NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 262 filers reported holding NEKTAR THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $166,000 | -55.0% | 51,961 | +141.6% | 0.02% | -56.8% |
| Q2 2021 | $369,000 | +73.2% | 21,503 | +67.4% | 0.04% | +8.8% |
| Q3 2020 | $213,000 | +6.0% | 12,847 | +14.0% | 0.03% | -12.8% |
| Q1 2020 | $201,000 | -73.8% | 11,271 | -10.2% | 0.04% | -63.2% |
| Q3 2018 | $766,000 | +273.7% | 12,557 | +266.7% | 0.11% | +194.4% |
| Q4 2017 | $205,000 | -50.2% | 3,424 | -85.7% | 0.04% | -67.3% |
| Q3 2016 | $412,000 | – | 23,948 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |